Unclaimed author profile

Gianluigi Condorelli

· Humanitas University

Is this your research profile?

Create or sign in to your KnowledgeTrend account to claim this page. After the claim, this same profile URL and its linked publications will belong to your account. Claiming does not automatically grant a verified badge.

Create account and claim this profile Sign in to claim

2Linked publications

0Citations

0h-index

0i10-index

Metrics are calculated from publications currently linked to this profile.

Researcher overview

About

Gianluigi Condorelli is a registered researcher in their academic field.

Research output

Recent Publications

2 research works linked to this profile

▤

Cardiac Ischemia and Reperfusion, Cardiac electrophysiology and arrhythmias, Anesthesia and Neurotoxicity Research · 2014 · Cardiovascular Research

ESC Working Group Cellular Biology of the Heart: Position Paper: improving the preclinical assessment of novel cardioprotective therapies

Sandrine Lecour, Hans Erik Bøtker, Gianluigi Condorelli, Sean M. Davidson, David García‐Dorado, Felix B. Engel, Péter Ferdinandy, G. Heusch, Rosalinda Madonna, Michel Ovize, Marisol Ruiz-Meana, Rainer Schulz, Joost P. G. Sluijter, Linda W. van Laake, Derek M. Yellon, Derek J. Hausenloy

Ischaemic heart disease (IHD) remains the leading cause of death and disability worldwide. As a result, novel therapies are still needed to protect the heart from the detrimental effects of acute ischaemia-reperfusion injury, in order to improve clinical outcomes in IHD patients. In this regard, although a large number of novel cardioprotective therapies discovered in the research laboratory have been investigated in the clinical setting, only a few of these have been demonstrated to improve clinical outcomes. One potential reason for this lack of success may have been the failure to thoroughly assess the cardioprotective efficacy of these novel therapies in suitably designed preclinical experimental animal models. Therefore, the aim of this Position Paper by the European Society of Cardiology Working Group Cellular Biology of the Heart is to provide recommendations for improving the preclinical assessment of novel cardioprotective therapies discovered in the research laboratory, with the aim of increasing the likelihood of success in translating these new treatments into improved clinical outcomes.

View Read PDF Download

▤

Cardiac Ischemia and Reperfusion, Cardiac electrophysiology and arrhythmias, Cardiac Arrest and Resuscitation · 2013 · Cardiovascular Research

Translating cardioprotection for patient benefit: position paper from the Working Group of Cellular Biology of the Heart of the European Society of Cardiology

Derek J. Hausenloy, Hans Erik Bøtker, Gianluigi Condorelli, Péter Ferdinandy, David García‐Dorado, Gerd Heusch, Sandrine Lecour, Linda W. van Laake, Rosalinda Madonna, Marisol Ruiz‐Meana, Rainer Schulz, Joost P. G. Sluijter, Derek M. Yellon, Michel Ovize

Coronary heart disease (CHD) is the leading cause of death and disability worldwide. Despite current therapy, the morbidity and mortality for patients with CHD remains significant. The most important manifestations of CHD arise from acute myocardial ischaemia-reperfusion injury (IRI) in terms of cardiomyocyte death and its long-term consequences. As such, new therapeutic interventions are required to protect the heart against the detrimental effects of acute IRI and improve clinical outcomes. Although a large number of cardioprotective therapies discovered in pre-clinical studies have been investigated in CHD patients, few have been translated into the clinical setting, and a significant number of these have failed to show any benefit in terms of reduced myocardial infarction and improved clinical outcomes. Because of this, there is currently no effective therapy for protecting the heart against the detrimental effects of acute IRI in patients with CHD. One major factor for this lack of success in translating cardioprotective therapies into the clinical setting can be attributed to problems with the clinical study design. Many of these clinical studies have not taken into consideration the important data provided from previously published pre-clinical and clinical studies. The overall aim of this ESC Working Group Cellular Biology of the Heart Position Paper is to provide recommendations for optimizing the design of clinical cardioprotection studies, which should hopefully result in new and effective therapeutic interventions for the future benefit of CHD patients.

View Read PDF Download